Novartis showcases Ph3 data for Fabhalta in IgAN as FDA grants priority review
Months after landing the first approval for the rare disease drug Fabhalta, Novartis is on track to potentially expand the label.
The FDA has granted priority review for the use of Fabhalta in IgA nephropathy, a rare kidney condition caused by the buildup of a protein known as IgA. Novartis announced the regulatory update in conjunction with a clinical readout where the drug reduced proteinuria, or elevated protein in urine.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.